<DOC>
	<DOCNO>NCT01344369</DOCNO>
	<brief_summary>The purpose study evaluate relative bioavailability test formulation norethindrone/ethinyl estradiol 0.4 mg/0.035 mg chewable tablet ( Teva Pharmaceuticals , USA ) compare reference list product , FEMCONÂ® Fe ( norethindrone/ethinyl estradiol ferrous fumarate ) 0.4 mg/0.035 mg Chewable tablet ( Warner Chilcott ) feed condition healthy , non-tobacco use , adult female subject .</brief_summary>
	<brief_title>Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Norinyl</mesh_term>
	<mesh_term>Norethindrone acetate , ethinyl estradiol , ferrous fumarate drug combination</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<criteria>Females , 1845 year age inclusive Body Mass Index within 1830 kg/m2 inclusive , describe Novum Standard Operating Procedures . Female subject must either abstain sexual intercourse use reliable nonhormonal method contraception ( e.g . condom spermicide , diaphragm , nonhormonal IUD ) least 14 day prior first study dosing , throughout study , 14 day last dose . Normal menstrual cycle . Good health determine lack clinically significant abnormality health assessment perform screen . Signed date informed consent form , meet criteria current FDA regulation . Post menopausal irregular menstrual cycle . Pregnant , lactating , likely become pregnant study . History drug hypersensitivity intolerance , opinion Investigator , would compromise safety subject study . Significant history current evidence chronic infectious disease , system disorder , organ dysfunction . Presence gastrointestinal disease history malabsorption within last year . History psychiatric disorder occur within last two year require hospitalization medication . Presence medical condition require regular treatment prescription drug . Use pharmacologic agent know significantly induce inhibit drugmetabolizing enzyme within 30 day prior dose . Participation clinical trial within 30 day prior dose . Drug alcohol addiction require treatment past 12 month . Donation significant loss whole blood ( 480 mL ) within 30 day plasma within 14 day prior dose . Positive test result HIV , Hepatitis B surface antigen , Hepatitis C antibody . Positive test result drug abuse screen . Positive serum pregnancy test . Subjects ever progestational hormone implant . Subjects progestational hormone depot injection within 12 month proceed dose . Subjects use use within 3 month precede dose vaginally administer estrogen progestincontaining product . Any personal strong family history estrogen progestogendependent tumor . History clinically significant fibrocystic breast disease . Subjects history thromboembolic disorder , myocardial infarction , stroke . Use norethindrone ethinyl estrodiolcontaining oral contraceptive within 30 day initial dosing . Hysterectomy oophorectomy ( unilateral bilateral ) User tobacco nicotine containing product within 30 day start study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Healthy Subjects</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>